Anacor to Present Preclinical Data on Orally Active PDE4 Inhibitor at the 8th Cytokines and Inflammation Conference
PALO ALTO, Calif.--(BUSINESS WIRE)--Jan 28, 2010 - Anacor Pharmaceuticals announced today that it will present a poster and oral presentation on a novel systemic anti-inflammatory candidate, AN6415, at the upcoming 8th Cytokines and Inflammation Conference, taking place January 28-29, 2010 in La Jolla, California.
Title: AN6415: A Novel, Highly Potent PDE4 Inhibitor with Oral Activity and Broad Spectrum Cytokine Suppression
About Anacor Pharmaceuticals
Anacor is a biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform. Anacor focused initially on developing topical applications of its compounds to treat fungal, bacterial and inflammatory diseases. In addition, the Company is developing systemic antibacterial therapeutics under a research and development agreement with GlaxoSmithKline. Anacor's most advanced product candidate is AN2690, a novel topical antifungal in development for the treatment of toenail onychomycosis, which is a fungal infection of the nail and nail bed. For more information visit www.anacor.com.
This press release may contain forward-looking statements that relate to future events and involve known and unknown risks, uncertainties and other factors that could cause actual levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. These statements reflect the views of Anacor as of the date of this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise publicly any forward- looking statements, whether as a result of new information, future events or otherwise after the date of this press release.
Contact: Anacor Pharmaceuticals
Anne Bowdidge, 650-543-7575
Posted: January 2010